-
Dr. Nanlin Li: Reshaping the Breast Cancer Treatment Landscape — Clinical Practice and Future Outlook of Weekly HDACi Entinostat
On April 24, 2024, a major milestone was achieved in China’s oncology landscape. The National Medical Products Administration (NMPA) granted official approval for entinostat, a domestically developed, selective histone deacetylase…
-
Dr. Ying Wang: Patient-Centered, Simplified Treatment to Optimize Chronic Disease Management — Entinostat Ushers in the Era of Weekly Therapy for HR+ Advanced Breast Cancer
Breast cancer remains the leading malignancy threatening women’s health worldwide. Among its subtypes, hormone receptor-positive/HER2-negative (HR+/HER2−) breast cancer is the most common and typically has a better prognosis, having now entered the era of chronic disease management. In the context of long-term, whole-course management—often spanning over a decade—the concept of “patient-centered care” has become central…
-
The First Weekly HDACi Regimen ! Entinostat Approved to Provide a New Potent and Convenient Option for Patients with HR+/HER2- Advanced Breast Cancer
Breast cancer is the most common malignancy among women worldwide, with the HR+/HER2- subtype being one of the most prevalent forms. With the rapid advancement of medical technology and the continuous emergence of new therapies, patient survival has significantly improved, bringing hope to many. Recently, the novel oral HDAC inhibitor entinostat received official approval from…
-
APASL 2025 Beijing Summit Approaches: Exploring New Frontiers in Multidisciplinary Collaboration for Liver Diseases
Dr. Lai Wei: Currently, two-thirds of global viral hepatitis cases are concentrated in Asia, with about half occurring in China. The World Health Organization (WHO) aims to reduce new viral hepatitis infections by 90% and related mortality by 65% by 2030. Thus, contributions from the Asia-Pacific region are pivotal in achieving these elimination goals.
-
2025 SGBCC Best Poster Awards Announced, Four Chinese Experts Crowned!
On March 13, 2025, the “2025 St. Gallen Breast Cancer Conference (SGBCC) Best Poster Awards” were grandly announced. A total of 482 posters were accepted for this year’s SGBCC
-
EAU 25 | Professors Samson Chan and Junlong Zhuang : PARPi Treatment Shows Initial Efficacy in mHSPC, Advancing Precision Therapy for Prostate Cancer
PARP inhibitors (PARPi) have ushered in a new era of precision treatment for prostate cancer. Multiple studies have confirmed that patients with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair deficiency mutations (HRRm) can benefit from this therapeutic approach. At the recently held 2025 European Association of Urology(EAU25) conference , a single-arm Phase II…
-
Prof. Benlong Yang Named First Chinese Scholar to Receive “Youth Education Ambassador” and “Social Media Ambassador” Titles at SGBCC
The 19th St. Gallen Breast Cancer Conference (SGBCC) took place in Vienna, Austria, from March 12 to 15, 2025. As one of the most prestigious biennial academic events in breast cancer research, SGBCC gathers leading global experts to discuss evolving treatment strategies for early breast cancer, voting on recommendations that shape clinical practice. Notably, this…
-
SGBCC Voice of China | Prof. Qiang Liu: Viewing Early Breast Cancer as a Systemic Disease from a ctDNA Perspective
Oncology Frontier: At this year’s SGBCC “Voice of China” session, you presented a report on dynamic ctDNA monitoring for stratifying relapse risk and guiding precision treatment in early TNBC. Could…
Connecting Medical Expertise through Media